The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a more substantial decrease in body size and improve metabolic health, particularl